Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation ...

Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented ...

Shares of the anti-aging biogenetics company Klotho Neurosciences are on retail investors' radars after the stock exploded ...

The U.S. FDA has granted orphan drug designation to Klotho Neurosciences Inc.’s secreted-Klotho (s-KL) promoter, gene and ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...